Cargando…

Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services

INTRODUCTION: Replacement therapy is constantly required by Hemophilia A (HA) patients lacking coagulation factor VIII (FVIII). The most serious complication of this treatment is the development of neutralizing antibodies (inhibitors). AIM: The aim of this study is to determine the frequency of FVII...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oudat, Raida, Al-Maharmeh, Muna, Al-Ghrayeb, Rasha, Ogeilat, Tunia, Mustafa, Maher Kh.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Medical Sciences of Bosnia and Herzegovina 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406006/ https://www.ncbi.nlm.nih.gov/pubmed/32801433 http://dx.doi.org/10.5455/medarh.2020.74.187-190

Ejemplares similares

Hematopoietic Stem Cell Transplantation in Thalassemia Patients: a Jordanian Single Centre Experience
por: Mustafa, Maher, et al.
Publicado: (2020)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A
por: Kim, Ju Young, et al.
Publicado: (2019)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
por: Hooimeijer, Louise H, et al.
Publicado: (2023)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
por: Hemşinlioğlu, Cansu, et al.
Publicado: (2023)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
por: Hart, Daniel P.
Publicado: (2020)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Development of an FVIII Inhibitor in a Mild Hemophilia Patient with a Phe595Cys Mutation
por: Yamanouchi, Jun, et al.
Publicado: (2018)

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
por: Liu, Chao Lien, et al.
Publicado: (2016)

Identification of FVIII gene mutations in patients with hemophilia A using new combinatorial sequencing by hybridization
por: Chetta, M., et al.
Publicado: (2008)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
por: Cai, Yuanhua, et al.
Publicado: (2020)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
por: El-Akabawy, Nadia, et al.
Publicado: (2020)

The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A
por: Zimta, Alina-Andreea, et al.
Publicado: (2021)

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1(+) Tregs
por: Becker-Gotot, Janine, et al.
Publicado: (2022)

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors
por: Okamoto, Shuichi, et al.
Publicado: (2019)

The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.
por: Bou-Jaoudeh, Melissa, et al.
Publicado: (2023)

Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A
por: Elnaggar, Muhammad, et al.
Publicado: (2019)

Association of Genetic Variant FVIII Gene and Factor VIII: A Pilot Study Among Hemophilia A Female Relatives in Saudi Arabia
por: Almohammadi, Abdullah T, et al.
Publicado: (2023)

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
por: Lytle, Allison M, et al.
Publicado: (2016)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
por: Trevisan, Brady, et al.
Publicado: (2021)

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A
por: Elkouby, Liron, et al.
Publicado: (2021)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
por: Ai, Di, et al.
Publicado: (2022)

A graph-based machine learning framework identifies critical properties of FVIII that lead to hemophilia A
por: Ferreira, Marcos V., et al.
Publicado: (2023)

Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors
por: Bravo, M I, et al.
Publicado: (2014)

Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients
por: Abu Al Karsaneh, Ola, et al.
Publicado: (2023)

Limited Generalizability of a Retrospective Chart Review Comparing 3 Recombinant FVIII Products for Hemophilia A Prophylaxis
por: Preblick, Ronald, et al.
Publicado: (2020)

Prevalence of Dental Fluorosis among Southern Jordanian Population
por: Al Warawreh, Amjad M., et al.
Publicado: (2020)

FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group
por: Chozie, Novie Amelia, et al.
Publicado: (2022)

A Scan of Pleiotropic Immune Mediated Disease Genes Identifies Novel Determinants of Baseline FVIII Inhibitor Status in Hemophilia-A
por: Howard, Tom, et al.
Publicado: (2023)

PB2649: THE SURGICAL OUTCOMES IN PEDIATRICS PATIENTS WITH HEMOPHILIA, THE ROYAL HOSPITAL EXPERIENCE, OMAN
por: Al Hajri, Alia, et al.
Publicado: (2023)

Attempts to treat patients with hemophilia, the "royal disease"
por: Park, Rojin
Publicado: (2013)

Health Status of the Clinical Dental Students in the Jordanian Universities
por: Badran, Darwish, et al.
Publicado: (2009)

P1662: OPTIMIZED PROPHYLAXIS BASED ON INDIVIDUALIZED TARGET TROUGH FVIII LEVEL IN PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A
por: Huang, K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uj8sdm1i5h5ndvs7rnank0dfpj